Clinical Trial Update: Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 trial comparing the safety and tolerability of PRO-231 versus VIGAMOXI on the ocular surface in healthy subjects has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Conjunctivitis

Drugs mentioned

• PRO-231
• VIGAMOXI

Snippet

Sponsor: Laboratorios Sophia S.A de C.V. | Conditions: Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | Phase 1 | Status: COMPLETED | Results posted: 2025-06-15